Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease - CIRI - Physiopathologie et biothérapies des infections muqueuses Accéder directement au contenu
Article Dans Une Revue Clinical Gastroenterology and Hepatology Année : 2019

Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease

Résumé

Ustekinumab is approved for treatment of Crohn's disease (CD).1,2 Few data are available to assess the usefulness of monitoring inflammatory biomarkers and therapeutic drug monitoring to predict response to ustekinumab. We conducted a prospective study to assess the relationships between these parameters and the clinical outcome at week 16 in active CD patients receiving ustekinumab.
Fichier principal
Vignette du fichier
S1542356519302484.pdf (180.43 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03489070 , version 1 (20-07-2022)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Ninon Soufflet, Gilles Boschetti, Xavier Roblin, Charlotte Cuercq, Nicolas Williet, et al.. Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology, 2019, 17, pp.2610 - 2612. ⟨10.1016/j.cgh.2019.02.042⟩. ⟨hal-03489070⟩
28 Consultations
43 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More